In this video interview, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation, discusses how MMRF goes beyond safety and efficacy data to help biopharmas research appropriate dosing for multiple myeloma therapies.
In a recent video interview with Applied Clinical Trials, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation (MMRF), discussed challenges in multiple myeloma clinical trials, including inefficiency, lack of focus on critical patient questions, and underrepresentation of diverse patient populations. Andreini also highlighted the Horizon clinical trial and how MMRF is working to address unmet need in the myeloma research space.
ACT: Despite many new therapies for multiple myeloma receiving FDA approval, why is there a lack of evidence for how to best use each treatment?
Andreini: Yeah, this is another great question, and taking a big step back, drug development led by biopharma companies appropriately focuses on proving out efficacy and safety for FDA approvals, right? And that's the right thing for biopharma companies to be focused on, but when new drugs come onto the market, that means that there's often a lack of evidence on how best to use these therapies in their approved indications, because they can't evaluate every combination and sequence and dosing schedule as part of that clinical development path to get the FDA approval, so this is where we, as an unbiased third party, as the MMRF, can really partner with biopharma companies to help fill in these evidence gaps, to inform, ultimately, what are the optimal uses of these agents and these approved indications.
What Can ClinOps Learn from Pre-Clinical?
August 10th 2021Dr. Hanne Bak, Senior Vice President of Preclinical Manufacturing and Process Development at Regeneron speaks about her role at the company as well as their work with monoclonal antibodies, the regulatory side of manufacturing, and more.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.